PMID- 7743797
OWN - NLM
STAT- MEDLINE
DCOM- 19950613
LR  - 20131121
IS  - 0277-3740 (Print)
IS  - 0277-3740 (Linking)
VI  - 14
IP  - 2
DP  - 1995 Mar
TI  - Topical and subcutaneous alpha-interferon fails to suppress corneal 
      neovascularization.
PG  - 147-51
AB  - Corneal neovascularization is a potentially blinding complication of a variety of 
      corneal disorders. alpha-Interferon has been shown to inhibit endothelial cell 
      migration and proliferation. It has been used successfully in the treatment of 
      pediatric pulmonary hemangioma and hairy cell leukemia. This study was undertaken 
      to evaluate the effect of topical and subcutaneous (s.c.) alpha-interferon on 
      corneal neovascularization. Corneal neovascularization was induced in 40 male New 
      Zealand white rabbits by placing silk sutures (7.0) bilaterally in each rabbit 
      eye at the 3 and 9 o'clock positions of the cornea, 3 mm from the limbus. Animals 
      were randomized into two main treatment groups for topical (group 1) and s.c. 
      (group 2) administration of interferon. Group 1 (n = 24) was then randomized into 
      four subgroups and treated daily with topical doses of (a) rabbit specific 
      alpha-interferon; (b) alpha-interferon plus 1% prednisolone acetate; (c) 1% 
      prednisolone acetate; and (d) buffered phosphate control. Group 2 (n = 16) was 
      randomized into two subgroups that received s.c. injections every other day of 
      (a) alpha-interferon and (b) phosphate buffer. Rate of corneal neovascularization 
      was documented photographically, with the end-point being the arrival of vessels 
      at the suture for each group. The results of this study indicated that at the 
      concentration and dosing regimens we used, neither topical nor s.c. 
      alpha-interferon inhibits the rate of corneal vascular growth significantly when 
      compared with our phosphate buffered solution control group (p = 0.88 and p = 
      0.84, respectively). Prednisolone acetate appeared to be the most effective in 
      inhibiting corneal neovascularization (p = 0.003).(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Nguyen, N
AU  - Nguyen N
AD  - Department of Ophthalmology, California Pacific Medical Center, San Francisco 
      94115, USA.
FAU - Goldberg, M
AU  - Goldberg M
FAU - Pico, J
AU  - Pico J
FAU - Kim, W
AU  - Kim W
FAU - Abbott, R L
AU  - Abbott RL
FAU - Levy, B
AU  - Levy B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cornea
JT  - Cornea
JID - 8216186
RN  - 0 (Interferon-alpha)
RN  - 0 (Ophthalmic Solutions)
RN  - 9PHQ9Y1OLM (Prednisolone)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Corneal Neovascularization/*therapy
MH  - Drug Therapy, Combination
MH  - Injections, Subcutaneous
MH  - Interferon-alpha/administration & dosage/*therapeutic use
MH  - Male
MH  - Ophthalmic Solutions
MH  - Prednisolone/therapeutic use
MH  - Rabbits
MH  - Random Allocation
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
PST - ppublish
SO  - Cornea. 1995 Mar;14(2):147-51.